Northwest Biotherapeutics reported $6.2M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agenus USD 78.81M 16.47M Jun/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Celldex Therapeutics USD 663.74M 61.2M Sep/2026
Eisai JPY 883.01B 121.38B Jun/2026
Merck USD 38.94B 2.26B Sep/2026
Northwest Biotherapeutics USD 6.2M 996K Mar/2026
Pfizer USD 45.01B 3.65B Sep/2026
Plus Therapeutics USD 11.77M 6.26M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026